CB1 agonist protective_against eating disorders
Evidence from:
primary |
all sources
Evidence (1 sources)
Shared genetic risk between eating disorder- and substance-use-related phenotypes: Evidence from genome-wide association studies.
(2021)
PMID:32064741
primary
initial evidence for the therapeutic effectiveness of cannabinoid agonists in treating eating disorders
confidence: 0.85